Anagenics Limited · ASX:AN1
Anagenics — Medical Therapies — Merger or Acquisition (May 2008)
24 slides from Anagenics's merger presentation, May 9, 2008
Slide 1: Midkine Portfolio Acquisition
Medical Therapies Limited Midkine Portfolio Acquisition 9 May 2008 1
Slide 2: Forward looking statements
Forward looking statements This presentation contains forward-looking statements. These statements are not guarantees of Medical Therapies Limited’s future performance and involve a number of risks and uncertainties that may cause actual results to differ materially from the results discussed in the
Slide 3: Midkine portfolio acquisition
Midkine portfolio acquisition Rationale for the acquisition of the midkine portfolio What is midkine? Details of the IP Agreement Midkine therapeutics portfolio Midkine diagnostics portfolio MTY post acquisition Timetable of key events 3
Slide 4: Rationale for midkine (MK) acquisition
Rationale for midkine (MK) acquisition Sound scientific principles Known composition and mechanism of action underlying the technology with clear Extensive in vitro and preclinical data (strong regulatory regulatory path and strong position) with a range of commercialisation opportunities commercial
Slide 5: Midkine
Midkine Discovered in 1988 by professors Muramatsu and Kadomatsu at Nagoya University Low molecular weight growth factor like protein (13kD) with two domains Highly expressed in oncogenesis, autoimmune and inflammatory diseases Midkine has a role in anti-apoptosis, cell migration, angiogenesis and c
Slide 6: Intellectual Property Agreement
Intellectual Property Agreement MTY will acquire from Cell Signals (CS) • Therapeutic applications for midkine the protein • 120+ anti-midkine antibodies with their therapeutic applications and anti- midkine nucleotides (cancer and autoimmune diseases such as MS) • Diagnostic applications of midkine
Slide 7: Midkine portfolio
Midkine portfolio Diagnostics MIDKINE Therapeutics Cancer Midkine Anti-midkine Anti-midkine protein antibodies nucleotides Sjogren’s syndrome Myocardial Cancer Cancer infarct Alzheimer’s disease Rheumatoid Endometriosis arthritis Rheumatoid arthritis Multiple sclerosis 7
Slide 8: Intellectual Property Portfolio
Intellectual Property Portfolio 28 patents covering use and manufacture of midkine, anti-midkine antibodies and anti-midkine nucleotides for diagnostic and therapeutic applications: • 120+ anti-midkine antibodies and all reagents • ELISA tests for • Early detection of cancer • Diagnosis of rheumatoi
Slide 9: Therapeutics Portfolio: Midkine
Therapeutics Portfolio: Midkine Using midkine and its protective function Midkine prevents apoptosis Midkine and increases blood vessel formation Midkine reduces damage from myocardial and cerebral infarct 9
Slide 10: Treatment for heart tissue damage
Treatment for heart tissue damage Addition of midkine reduces heart tissue injury in animal models by reducing apoptosis and increasing angiogenesis Pig model Mouse model Control Midkine treated Apoptosis Control Midkine treated Mortality rate after 24h: Control Midkine treated •Control: 4/12 (33.3%
Slide 11: Therapeutics portfolio: Midkine inhibitors
Therapeutics portfolio: Midkine inhibitors Inhibition of midkine using anti-midkine antibodies and nucleotides Inhibition of midkine is potential treatment Solid Tumours Rheumatoid arthritis Midkine is expressed during Multiple sclerosis oncogenesis, inflammation Endometriosis and tissue repair 11
Slide 12: Treatment for rectal carcinoma
Treatment for rectal carcinoma Anti-midkine antisense DNA directed to suppress growth of mouse rectal carcinoma cells (CMT-93) (Takei et al, 2001) 12
Slide 13: Treatment for multiple sclerosis
Treatment for multiple sclerosis MS symptoms are reduced when MOG35-55 is administered to mice with no midkine genes (Wang et al, 2008) MK-KO mice show delay in disease onset and reduction in disease severity after immunisation with MOG35-55 13
Slide 14: Treatment for rheumatoid arthritis
Treatment for rheumatoid arthritis MK as a new target for treating RA (Maruyama et al, 2004) No. of mice Incidence (%) arthritis + - WT 6 1 86 KO-MK 1 9 10 MK pump 9 3 75 • 6/7 (86%) WT mice show symptoms from antibody-induced arthritis Increased levels of MK in patients with RA • 1/10 of MK-KO (10%
Slide 15: Global markets for key indications
Global markets for key indications INDICATION GLOBAL TREATMENT GLOBAL MARKET PREVALENCE (US$) Acute myocardial infarct ~ 32 million heart • Surgery • Cardiovascular drugs attacks / year • ACE inhibitors worth ~ $82.4 billion in • Beta blockers 2007 • Fibrinolysis Cancer ~ 25 million Chemotherapy • $
Slide 16: Therapeutic portfolio
Therapeutic portfolio 2008 2009 2010 2011 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Acute myocardial Preclinical Phase 1/2A Phase 2B infarct Multiple Preclinical Phase 1/2A Phase 2B sclerosis Preclinical Phase 1/2A Phase 2B Cancer 16
Slide 17: Diagnostic Products
Diagnostic Products Detection of midkine using Enzyme-linked Immunoassay (ELISA) 17
Slide 18: Incidence and cost of cancer
Incidence and cost of cancer Almost 11 million new cases of cancer diagnosed each year globally Mouth and oropharynx cancers “Top Ten” Cancers Worldwide Cervix uteri cancer Oesophageal cancer Lymphoma, multiple myeloma Prostate cancer Liver cancer Stomach cancer Breast cancer Colon/rectum cancer Tra
Slide 19: Breast cancer diagnostic
Breast cancer diagnostic Midkine detected in 45.5% of stage 0 breast cancers 19
Slide 20: Neuroblastoma Diagnostic
Neuroblastoma Diagnostic Correlation of elevated level of blood midkine with poor prognostic factor of human neuroblastomas (Ikematsu et al, 2003) 20
Slide 21: Diagnostic Portfolio
Diagnostic Portfolio 2008 2009 2010 2011 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Cancer Research use Clinical validation (AUS, EU) Clinical validation (JP, US) Rheumatoid Research use Arthritis Alzheimer’s Clinical validation (AUS, EU) disease Clinical validation (JP, US) Sjogren’s Research
Slide 22: MTY – Post Acquisition
MTY – Post Acquisition Capital structure Shares 74,085,624 New Shares (NS Capital Co) 23,500,000 New Shares (Cell Signals) 20,000,000 Total shares on issue 117,585,624 Options (Employee) 7,505,000 Convertible notes 9,381,096 Operations • Sydney will remain the pre-clinical/clinical and administrativ
Slide 23: Proposed timetable of key events
Proposed timetable of key events* EGM Notice 15 May 2008 Shareholder briefings 16 May – 10 June 2008 EGM 16 June 2008 Issuing of shares under the IP Agreement 18 June 2008 Settlement of IP Agreement 19 June 2008 *This timetable is subject to change 23
Slide 24: Contact Maria Halasz
CONTACT Maria Halasz CEO and Managing Director Level 6, 40 King Street Sydney NSW 2000 M +61416 008 413 E [email protected] T +61 2 9299 0311 www.medicaltherapies.com.au 24